Journal of Medical Economics
Volume 27, 2024 - Issue 1
Open access
1,478
Views
0
CrossRef citations to date
0
Altmetric
Oncology
Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data
Alexandra S. Vitkoa Value, Evidence, and Outcomes (VEO) – Oncology, Eli Lilly and Company, Indianapolis, IN, USAView further author information
, Pam Martinb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information
, Sheng Zhangb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information
, Adam Johnstonb Medical Decision Modeling Inc, Indianapolis, IN, USAView further author information
, Robert Ohsfeldtb Medical Decision Modeling Inc, Indianapolis, IN, USA;c Texas A&M University, College Station, TX, USAView further author information
, Shen Zhengd TechData Service Company, King of Prussia, PA, USAView further author information
& Astra M. Liepaa Value, Evidence, and Outcomes (VEO) – Oncology, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
View further author information
show allView further author information
Pages 84-96
|
Received 08 Jun 2023, Accepted 01 Dec 2023, Published online: 19 Dec 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.